GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » F-star Therapeutics Inc (NAS:FSTX) » Definitions » ROC (Joel Greenblatt) %

F-star Therapeutics (F-star Therapeutics) ROC (Joel Greenblatt) % : -2,074.39% (As of Sep. 2022)


View and export this data going back to 2020. Start your Free Trial

What is F-star Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. F-star Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was -2,074.39%.

The historical rank and industry rank for F-star Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

FSTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1132.59   Med: -878.78   Max: -796.25
Current: -1132.59

During the past 3 years, F-star Therapeutics's highest ROC (Joel Greenblatt) % was -796.25%. The lowest was -1132.59%. And the median was -878.78%.

FSTX's ROC (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -334.375 vs FSTX: -1132.59

F-star Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


F-star Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for F-star Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

F-star Therapeutics ROC (Joel Greenblatt) % Chart

F-star Therapeutics Annual Data
Trend Dec19 Dec20 Dec21
ROC (Joel Greenblatt) %
-902.81 -878.78 -796.25

F-star Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -888.17 414.84 -1,186.05 -2,031.02 -2,074.39

Competitive Comparison of F-star Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, F-star Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


F-star Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, F-star Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where F-star Therapeutics's ROC (Joel Greenblatt) % falls into.



F-star Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 4.825) - (10.272 + 0 + 3.83)
=-9.277

Working Capital(Q: Sep. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 5.896) - (7.72 + 0 + 4.814)
=-6.638

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of F-star Therapeutics for the quarter that ended in Sep. 2022 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2022 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2022  Q: Sep. 2022
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-72.116/( ( (3.573 + max(-9.277, 0)) + (3.38 + max(-6.638, 0)) )/ 2 )
=-72.116/( ( 3.573 + 3.38 )/ 2 )
=-72.116/3.4765
=-2,074.39 %

Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


F-star Therapeutics  (NAS:FSTX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


F-star Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of F-star Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


F-star Therapeutics (F-star Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Babraham Research Campus, Eddeva B920, Cambridge, GBR, CB22 3AT
F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.
Executives
Geoffrey Race director C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Edward Jr Benz director C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Darlene M Deptula-hicks officer: See Remarks C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Eliot Forster director, officer: PRESIDENT AND CEO C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Nessan Bermingham director 890 WINTER STREET, WALTHAM MA 02451
Louis Kayitalire officer: CHIEF MEDICAL OFFICER C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Neil Brewis officer: CHIEF SCIENTIFIC OFFICER C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pamela M. Klein director 35 PARKWOOD DRIVE, SUITE 210, HOPKINTON MA 01748
Krol Patrick Johan Hendrik director GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Garrett Winslow officer: General Counsel and Secretary 35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Lori Firmani officer: VP of Finance and Treasurer 35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTCALS, INC., HOPKINTON MA 01748
Scott Andrew Smith director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Timothy P Clackson director C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christiana Bardon director, 10 percent owner 86 SOUTH STREET, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Mpm Oncology Impact Management Lp 10 percent owner 399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116

F-star Therapeutics (F-star Therapeutics) Headlines

From GuruFocus

Lifshitz Law PLLC Announces Investigation of FSTX, MBCN, RDUS, and ZEN

By GuruFocusNews GuruFocusNews 07-09-2022